Global Ivosidenib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ivosidenib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer.
Ivosidenib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ivosidenib market is projected to reach US$ 238.5 million in 2029, increasing from US$ 175.3 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
Ivosidenib's market driver is its efficacy in treating relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. It inhibits the mutated IDH1 enzyme, leading to remission. The niche target population and limited treatment options contribute to its growth. However, challenges include potential side effects, the need for genetic testing to identify eligible patients, and competition from other AML therapies. Despite challenges, Ivosidenib's promising results and ongoing research in AML with IDH1 mutations present opportunities for market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ivosidenib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Servier Pharmaceuticals
Segment by Type
60 Tablets
30 Tablets
Hospital
Pharmacy
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ivosidenib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ivosidenib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ivosidenib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Ivosidenib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ivosidenib introduction, etc. Ivosidenib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ivosidenib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Ivosidenib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ivosidenib market is projected to reach US$ 238.5 million in 2029, increasing from US$ 175.3 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
Ivosidenib's market driver is its efficacy in treating relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. It inhibits the mutated IDH1 enzyme, leading to remission. The niche target population and limited treatment options contribute to its growth. However, challenges include potential side effects, the need for genetic testing to identify eligible patients, and competition from other AML therapies. Despite challenges, Ivosidenib's promising results and ongoing research in AML with IDH1 mutations present opportunities for market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ivosidenib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Servier Pharmaceuticals
Segment by Type
60 Tablets
30 Tablets
Segment by Application
Hospital
Pharmacy
Segment by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ivosidenib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ivosidenib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ivosidenib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Ivosidenib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ivosidenib introduction, etc. Ivosidenib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ivosidenib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices